期刊文献+

米诺膦酸二聚体的合成和结构确证

Synthesis and Structural Confirmation of the Dimer of Minodronic Acid
原文传递
导出
摘要 为控制米诺膦酸的质量,基于生产工艺确定其存在二聚体有关物质。采用2-(咪唑并[1,2-a]吡啶-3-基)乙酸为原料,仅使用单一磷酸化试剂三氯化磷,甲磺酸(5.5倍物质的量)作为反应溶剂,在温和条件下即实现了米诺膦酸二聚体,即[2,5-二羟基-3,6-双(咪唑[1,2-a]吡啶-3-基甲基)-2,5-二氧基-1,4,2,5-二氧二膦-3,6-二酰基]双(膦酸)的高效合成,收率达到50%以上,纯度不低于99.0%,结构经^(1)H NMR、^(13)C NMR、^(31)P NMR和HRMS确证,可作为米诺膦酸质量研究的对照品。 In order to control the quality of minodronic acid,this study determined the dimer,[2,5-dihydroxy-3,6-bis(imidazole[1,2-a]pyridin-3-ylmethyl)-2,5-dioxo-1,4,2,5-dioxodiphosphine-3,6-diacyl]bis(phosphonic acid),a relative substance of minodronic acid based on the production process of minodronic acid.It was obtained by the new strategy by reaction of 2-(imidazo[1,2-a]pyridin-3-yl)acetic acid with phosphorus trichloride in methanesulfonic acid(5.5 times amount of substance).The yield was more than 50%,and the purity was not less than 99.0%.The structure of the dimer was confirmed by ^(1)H NMR,^(13)C NMR,^(31)P NMR and high resolution mass spectrometry(HRMS),which could be used as a standard for the quality study of minodronic acid.
作者 朱冉冉 田天恩 王建耀 董志奎 ZHU Ranran;TIAN Tianen;WANG Jianyao;DONG Zhikui(Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical Co.,Ltd.,Beijing 102206)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2022年第4期474-476,共3页 Chinese Journal of Pharmaceuticals
关键词 米诺膦酸 有关物质 质量控制 二聚体 结构确证 minodronic acid relative substance quality control dimer structure confirmation
  • 相关文献

参考文献4

二级参考文献20

  • 1[1]Isomura Y, Takeuchi M, Abe T. Heterocyclic bisphosphonic acid derivatives as bone resorption inhibitors [P]. EP: 354806,1990-02-14. (CA 1990, 113: 24240)
  • 2[2]Yoshida Y, Moriya A, Kitamura K, et al. Response of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction [J]. J Bone Miner Res, 1998, 13 (6): 1011-1022.
  • 3[3]Sasaki A, Kitimura K, Alcalde RE, et al. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice [J]. Int J Cancer, 1998, 77 (2): 279-285.
  • 4[4]Almirante L, Mugnaini A, Friz LP, et al. Sintesi e reazioni di derivati dell' imidazolo[J]. Boll Chlm Farm, 1966, 105:32-43.
  • 5[5]Almiarante L. Synthesis and pharmacological activities of nitriles, amides, and carboxylic acid derivatives of imidazo [ 1,2-α] pyridine [J]. JMed Chem, 1969, 12 (1): 122-126.
  • 6Kubo T,Shimose S,Matsuo T,et al.Minodronate for thetreatment of osteoporosis[J].Drugs Today(Barc),2010,46(1):33-37.
  • 7Takeuchi M,Sakamoto S,Kawamuki K,et al.Studieson novel bone resorption inhibitors.Ⅱ.Synthesisand pharmacological activities of fused aza-heteroarylbisphosphonate derivatives[J].Chem Pharm Bull,1998,46(11):1703-1709.
  • 8杨利民.一种高纯度的米诺膦酸及其制备方法:中国,101531681[P].2009-09-16.
  • 9Akihiko N,Takayuki D,Isao K.Production of4-bromo-acetoacetic ester compound:JP,2000336064[P].2000-12-05.
  • 10Almirante L,Mugnaini A,Rugarli P,et al.Derivatives of imidazole.Ⅲ.Synthesis and pharmacological activities ofnitriles,amides,and carboxylic acid derivatives of imidazo-[1,2-a]pyridine[J].J Med Chem,1969,12(1):122-126.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部